Improving Cell Line Development Efficiency With AbZelect™

Reaching clinical trials with your innovative biologic is paramount, but cell line development bottlenecks can stall progress. Abzena's AbZelect™ and AbZelectPRO™ platforms cut through these delays, reducing timelines to just 15 weeks from sequence to research cell bank.

This revolutionary approach optimizes the vector, host cell line, and process, yielding high-performing, stable CHO cell lines for efficient protein and vaccine production. Early generation of diverse, fast-growing pools allows for in-depth characterization and proactive risk mitigation, ensuring a smooth path to IND filing.

Backed by Abzena's deep expertise and ICH-compliant analytics platform, you gain invaluable insights and a comprehensive report for seamless IND integration. Don't let cell line development hold you back – review the advantages of two innovative, accelerated CLD platforms and unlock the potential of your biologics.